Fatty Liver Disease Market Pipeline 2017 Industry Share for Novartis, Celgene, NGM Biopharmaceuticals, and Others

Fatty Liver Disease Therapeutics Market report provides the composition of the FLD market in terms of dominant classes of therapies. Key unmet needs are identified to allow a competitive understanding of gaps in the market.

April 27, 2017 /MarketersMedia/ —

The report “Frontier Pharma: Fatty Liver Disease Pipeline Market - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products” helps to understand the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and algorithms.

Browse the Fatty Liver Disease Pipeline Market 2017 Report of 76 Pages, 58 Tables and Figures, and 10 Companies Available at http://www.reportsnreports.com/contacts/discount.aspx?name=974419.

Fatty liver disease (FLD) Market comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation in the liver (steatosis), which may lead to inflammation (steatohepatitis) and fibrosis. It has the potential to progress to end-stage liver diseases such as cirrhosis, liver cancer and liver failure. It is also associated with numerous complications and co-morbidities, including cardiovascular and metabolic diseases. FLD can be divided into non-alcoholic FLD (NAFLD) and alcoholic FLD (AFLD), depending on the history of alcohol use. Both can also be divided into two subgroups: steatosis and steatohepatitis.

This Report Covered Below Points
• Provides the composition of the FLD market in terms of dominant classes of therapies. Key unmet needs are identified to allow a competitive understanding of gaps in the market.
• Allows recognizing innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix tailored to FLD, all first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=974419.
Companies mentioned in this report: Novartis, Celgene, NGM Biopharmaceuticals, Raptor Pharmaceuticals, chemomAb, Conatus Pharmaceuticals, BLR Bio.

Scope of the Report
FLD comprises a diverse patient population with significant unmet needs
The FLD pipeline is relatively large and has a high degree of first-in-class innovation
The FLD deal landscape shows rising deal volumes and considerable investment opportunities

List of Tables
Table 1: Fatty Liver Disease Therapeutics Market, Survival Rates of Simple Steatosis and NASH/ASH, 2017
Table 2: Fatty Liver Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Connective Tissue Growth Factor, 2017
Table 3: Fatty Liver Disease Therapeutics Market, Global, Pipeline Programs Targeting Connective Tissue Growth Factor, 2017
Table 4: Fatty Liver Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Sterol Regulatory Element-Binding Protein 1, 2017
Table 5: Fatty Liver Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Sterol Regulatory Element-Binding Protein 2, 2017
And More…

List of Figures
Figure 1: Fatty Liver Disease Therapeutics Market, US, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Product Approvals, 1987-2014
Figure 2: Fatty Liver Disease Therapeutics Market, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval ($m), 2006-2013
Figure 3: Fatty Liver Disease Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
Figure 4: Fatty Liver Disease Therapeutics Market, Global, Pipeline by Stage of Development and Molecule Type, 2017
And More…

In Depth Table of Content for Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact Info:
Name: Ritesh Tiwari
Email: [email protected]
Organization: ReportsnReports.com
Phone: + 1 888 391 5441

Source URL: http://marketersmedia.com/fatty-liver-disease-market-pipeline-2017-industry-share-for-novartis-celgene-ngm-biopharmaceuticals-and-others/191499

For more information, please visit http://www.reportsnreports.com/reports/974419-frontier-pharma-fatty-liver-disease-high-degree-of-first-in-class-innovation-dominated-by-nuclear-receptor-targeting-nash-products.html

Source: MarketersMedia

Release ID: 191499